Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation
Semra Palić, Patrick A. Bhairosing, Jos H. Beijnen, et al.
Antimicrobial Agents and Chemotherapy (2019) Vol. 63, Iss. 7
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

Unmasking the Mechanism behind Miltefosine: Revealing the Disruption of Intracellular Ca2+ Homeostasis as a Rational Therapeutic Target in Leishmaniasis and Chagas Disease
Gustavo Benaím, Alberto Paniz‐Mondolfi
Biomolecules (2024) Vol. 14, Iss. 4, pp. 406-406
Open Access | Times Cited: 9
An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis
Semra Palić, Jos H. Beijnen, Thomas P. C. Dorlo
International Journal of Antimicrobial Agents (2021) Vol. 59, Iss. 1, pp. 106459-106459
Closed Access | Times Cited: 53
Glutamine supplementation improves the efficacy of miltefosine treatment for visceral leishmaniasis
Carolina Ferreira, Inês Mesquita, Ana Margarida Barbosa, et al.
PLoS neglected tropical diseases (2020) Vol. 14, Iss. 3, pp. e0008125-e0008125
Open Access | Times Cited: 30
Anti-Parasitics with a Triple Threat: Targeting Parasite Enzymes, the Proton Motive Force, and Host Cell-Mediated Killing
Akanksha M. Pandey, Satish R. Malwal, Mariana Valladares-Delgado, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Anti-Parasitics with a Triple Threat: Targeting Parasite Enzymes, the Proton Motive Force, and Host Cell-Mediated Killing
Akanksha M. Pandey, Satish R. Malwal, Mariana Valladares-Delgado, et al.
ACS Infectious Diseases (2025)
Closed Access
A clioquinol-containing Pluronic® F127 polymeric micelle system is effective in the treatment of visceral leishmaniasis in a murine model
Grasiele S.V. Tavares, Débora V.C. Mendonça, Isabela A.G. Pereira, et al.
Parasite (2020) Vol. 27, pp. 29-29
Open Access | Times Cited: 26
Unmasking the Mechanism behind Miltefosine: Revealing the Disruption of Intracellular Ca2+ Homeostasis as a Rational Therapeutic Target in Leishmaniasis and Chagas Disease
Gustavo Benaím, Alberto Paniz‐Mondolfi
(2024)
Open Access | Times Cited: 3
Appraisal of Chitosan-Coated Lipid Nano-Combination with Miltefosine and Albendazole in the Treatment of Murine Trichinellosis: Experimental Study with Evaluation of Immunological and Immunohistochemical Parameters
A Ibrahim, Sahar Selim, Dalia Shafey, et al.
Acta Parasitologica (2024) Vol. 69, Iss. 1, pp. 929-950
Open Access | Times Cited: 3
Tolerability and Safety of Miltefosine for the Treatment of Cutaneous Leishmaniasis
Nadav Astman, Chen Arbel, Oren Katz, et al.
Tropical Medicine and Infectious Disease (2024) Vol. 9, Iss. 9, pp. 218-218
Open Access | Times Cited: 3
Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral Leishmaniasis
Daniela P. Lage, Patrícia A.F. Ribeiro, Daniel Dias, et al.
Vaccines (2020) Vol. 8, Iss. 2, pp. 289-289
Open Access | Times Cited: 21
Can We Harness Immune Responses to Improve Drug Treatment in Leishmaniasis?
Raphael Taiwo Aruleba, Katharine C. Carter, Frank Brombacher, et al.
Microorganisms (2020) Vol. 8, Iss. 7, pp. 1069-1069
Open Access | Times Cited: 19
Differences in the Cellular Immune Response during and after Treatment of Sudanese Patients with Post-kala-azar Dermal Leishmaniasis, and Possible Implications for Outcome
A. Torres, Brima M. Younis, Mohammed Alamin, et al.
Journal of Epidemiology and Global Health (2024) Vol. 14, Iss. 3, pp. 1167-1179
Open Access | Times Cited: 2
Impact of clinically acquired miltefosine resistance by Leishmania infantum on mouse and sand fly infection
Lieselotte Van Bockstal, Dimitri Bulté, Sarah Hendrickx, et al.
International Journal for Parasitology Drugs and Drug Resistance (2020) Vol. 13, pp. 16-21
Open Access | Times Cited: 18
The importance of T cell-derived cytokines in post-kala-azar dermal leishmaniasis
Abdollah Jafarzadeh, Sara Jafarzadeh, Iraj Sharifi, et al.
Cytokine (2020) Vol. 147, pp. 155321-155321
Closed Access | Times Cited: 17
Total Phenolic Fraction (TPF) from Extra Virgin Olive Oil: Induction of apoptotic-like cell death in Leishmania spp. promastigotes and in vivo potential of therapeutic immunomodulation
Kalliopi Karampetsou, Olga S. Koutsoni, Georgia Gogou, et al.
PLoS neglected tropical diseases (2021) Vol. 15, Iss. 1, pp. e0008968-e0008968
Open Access | Times Cited: 16
3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine
Juliana B. T. Carnielli, Anuja Dave, Audrey Romano, et al.
EBioMedicine (2022) Vol. 86, pp. 104378-104378
Open Access | Times Cited: 11
Cytokines and metabolic regulation: A framework of bidirectional influences affecting Leishmania infection
Neelam Bodhale, Mareike Ohms, Carolina Ferreira, et al.
Cytokine (2020) Vol. 147, pp. 155267-155267
Closed Access | Times Cited: 16
Synergic effect of eugenol oleate with amphotericin B augments anti-leishmanial immune response in experimental visceral leishmaniasis in vitro and in vivo
Amrita Kar, Adithyan Jayaraman, Mamilla R. Charan Raja, et al.
International Immunopharmacology (2020) Vol. 91, pp. 107291-107291
Closed Access | Times Cited: 15
Efficacy of topical Miltefosine formulations in an experimental model of cutaneous leishmaniasis
M. Peralta, Nadina Usseglio, Ma. Estefanía Bracamonte, et al.
Drug Delivery and Translational Research (2021) Vol. 12, Iss. 1, pp. 180-196
Closed Access | Times Cited: 14
Antileishmanial activity and immunomodulatory effect of secosubamolide, a butanolide isolated from Nectandra oppositifolia (Lauraceae)
Thais A. Costa‐Silva, Geanne A. Alves Conserva, Andrés Jimenez Galisteo, et al.
˜The œJournal of venomous animals and toxins including tropical diseases (2019) Vol. 25
Open Access | Times Cited: 14
Pamidronate, a promising repositioning drug to treat leishmaniasis, displays antileishmanial and immunomodulatory potential
Juliana Martins Ribeiro, Marina L. Rodrigues‐Alves, Edward Oliveira, et al.
International Immunopharmacology (2022) Vol. 110, pp. 108952-108952
Closed Access | Times Cited: 9
Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study
Anke E Kip, Séverine Blesson, Fabiana Alves, et al.
Journal of Antimicrobial Chemotherapy (2021) Vol. 76, Iss. 5, pp. 1258-1268
Open Access | Times Cited: 11
Milteforan, a promising veterinary commercial product against feline sporotrichosis
Laura C. García Carnero, Camila Figueiredo Pinzan, Camila Diehl, et al.
Microbiology Spectrum (2024) Vol. 12, Iss. 10
Open Access | Times Cited: 1
Working towards the development of vaccines and chemotherapeutics against neosporosis—With all of its ups and downs—Looking ahead
Dennis Imhof, Kai Pascal Alexander Hänggeli, Maria Cristina Ferreira de Sousa, et al.
Advances in Parasitology/Advances in parasitology (2024), pp. 91-154
Closed Access | Times Cited: 1
Milteforan, a promising veterinary commercial product against feline sporotrichosis
Laura C. García Carnero, Thaila Fernanda dos Reis, Camila Diehl, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top